# ClinicalTrials.gov record NCT02416271

> PeptideScanner retained ClinicalTrials.gov record NCT02416271 at 2026-07-30T21:42:40.803Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct02416271-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-04-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02416271-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02416271-teriparatide-v1.json
- Content SHA-256: `a31ea1f9c3ccf8e1204baa4f42f62f59043d9abd67ad6e147c27d60b789a9816`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02416271 ([`ctg-observation-nct02416271-2015-04-14-2e5287f7cbae`](#source-ctg-observation-nct02416271-2015-04-14-2e5287f7cbae))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02416271 at 2026-07-30T21:42:40.803Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02416271-2015-04-14-2e5287f7cbae`](#source-ctg-observation-nct02416271-2015-04-14-2e5287f7cbae))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02416271 at 2026-07-30T21:42:40.803Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02416271-2015-04-14-2e5287f7cbae`](#source-ctg-observation-nct02416271-2015-04-14-2e5287f7cbae))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02416271-2015-04-14-2e5287f7cbae`](#source-ctg-observation-nct02416271-2015-04-14-2e5287f7cbae))

## Sources

<a id="source-ctg-observation-nct02416271-2015-04-14-2e5287f7cbae"></a>
- **ClinicalTrials.gov record NCT02416271 · retained source version 2015-04-14:2e5287f7cbaeeb59262fbc1baba3868b2395a5ccab9106c9aa9e61fd3b77e9b6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02416271) (`ctg-observation-nct02416271-2015-04-14-2e5287f7cbae`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02416271." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02416271-teriparatide-v1.json SHA-256: a31ea1f9c3ccf8e1204baa4f42f62f59043d9abd67ad6e147c27d60b789a9816.